Sanofi-aventis and Regeneron Report Positive Phase III Results With ZALTRAP in Second-line Metastatic Colorectal Cancer

Sanofi-aventis SNY and Regeneron Pharmaceuticals, Inc. REGN today announced that the Phase III VELOUR trial evaluating the investigational agent ZALTRAP™ , also known as VEGF Trap, in combination with the FOLFIRI chemotherapy regimen, 5-fluorouracil, and irinotecan] versus a regimen of FOLFIRI plus placebo met its primary endpoint of improving overall survival (OS) in the second-line treatment of metastatic colorectal cancer. The most frequent adverse events reported with ZALTRAP in combination with FOLFIRI were diarrhea, asthenia/fatigue, stomatitis and ulceration, nausea, infection, hypertension, gastrointestinal and abdominal pains, vomiting, decreased appetite, decreased weight, epistaxis, alopecia, and dysphonia.